

REMARKS

The claims have been amended to place them in a format more customary to US patent practice. Support for new claim 16 can be found, for example, in original claim 2. Support for new claim 17 can be found, for example, in original claim 5. Support for new claim 18 can be found, for example, in original claim 6. Support for new claim 19 can be found, for example, in original claim 7. Support for new claim 20 can be found for example in original claim 8. No new matter has been added.

The Rejections Under 35 USC § 112

The rejections are overcome by the amendments to the claims. Thus, it is respectfully requested that the rejection be withdrawn.

Rejections under 35 USC §102

It is believed that the amendments to the claims render the rejection under 35 USC §102 moot.

The references are silent regarding treating dyslipidaemia, atherosclerosis or diabetes comprising administering a compound of the formula I.

As can be seen on page 23 last paragraph to page 24 of the specification, the activity of the compounds of the invention leading to a hypolipidaemiant and hypoglycaemiant effect were demonstrated *in vitro*.

Thus, it is respectfully requested that the rejection be withdrawn.

Double Patenting Rejections

A terminal disclaimer is filed herewith overcoming these rejections.

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,
/Richard Traverso/

Richard Traverso, Reg. No. 30,595
Attorney/Agent for Applicant(s)

/Jennifer Branigan/
Jennifer Branigan, Reg. No. 40,921
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: **MERCK-3129**
Date: **22 June 2009**